Marker Cash vs Cash And Short Term Investments Analysis

MRKR Stock  USD 3.19  0.07  2.15%   
Marker Therapeutics financial indicator trend analysis is infinitely more than just investigating Marker Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marker Therapeutics is a good investment. Please check the relationship between Marker Therapeutics Cash and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Cash vs Cash And Short Term Investments

Cash vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marker Therapeutics Cash account and Cash And Short Term Investments. At this time, the significance of the direction appears to have totally related.
The correlation between Marker Therapeutics' Cash and Cash And Short Term Investments is 1.0. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Marker Therapeutics, assuming nothing else is changed. The correlation between historical values of Marker Therapeutics' Cash and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Marker Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Cash i.e., Marker Therapeutics' Cash and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

1.0
Relationship DirectionPositive 
Relationship StrengthVery Strong

Cash

Cash refers to the most liquid asset of Marker Therapeutics, which is listed under current asset account on Marker Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Marker Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Marker Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Marker Therapeutics balance sheet. This account contains Marker Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Marker Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Marker Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.As of 11/27/2024, Enterprise Value is likely to grow to about 27.1 M, while Selling General Administrative is likely to drop slightly above 5.6 M.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation3.2M3.7M4.2M2.3M
Interest Income5.7K248.1K447.2K291.5K

Marker Therapeutics fundamental ratios Correlations

0.49-0.040.070.930.48-0.81-0.720.690.920.650.920.19-0.050.540.55-0.450.670.750.360.50.95-0.130.06-0.180.34
0.49-0.030.140.340.97-0.06-0.740.680.210.760.210.590.190.810.7-0.270.880.730.490.970.270.280.04-0.720.82
-0.04-0.030.94-0.34-0.010.070.020.07-0.060.04-0.06-0.020.23-0.060.03-0.18-0.02-0.060.76-0.01-0.06-0.130.240.06-0.01
0.070.140.94-0.270.10.08-0.040.31-0.020.23-0.020.010.440.010.28-0.220.130.00.890.11-0.010.150.470.060.07
0.930.34-0.34-0.270.34-0.88-0.660.490.940.440.940.12-0.190.470.34-0.360.540.710.00.360.95-0.21-0.1-0.130.26
0.480.97-0.010.10.34-0.1-0.830.560.220.690.220.680.020.910.55-0.290.910.810.421.00.270.08-0.18-0.780.91
-0.81-0.060.070.08-0.88-0.10.54-0.32-0.97-0.09-0.970.110.12-0.310.00.38-0.3-0.590.02-0.12-0.950.290.03-0.1-0.1
-0.72-0.740.02-0.04-0.66-0.830.54-0.44-0.59-0.55-0.59-0.650.07-0.94-0.350.56-0.86-1.0-0.29-0.83-0.640.160.280.67-0.81
0.690.680.070.310.490.56-0.32-0.440.490.760.49-0.020.210.390.82-0.250.670.450.620.60.520.30.43-0.060.37
0.920.21-0.06-0.020.940.22-0.97-0.590.490.311.0-0.04-0.070.360.24-0.410.430.640.140.241.0-0.210.060.030.15
0.650.760.040.230.440.69-0.09-0.550.760.310.310.470.020.520.93-0.270.770.530.650.710.370.10.09-0.450.46
0.920.21-0.06-0.020.940.22-0.97-0.590.491.00.31-0.04-0.070.360.24-0.410.430.640.140.241.0-0.210.060.030.15
0.190.59-0.020.010.120.680.11-0.65-0.02-0.040.47-0.040.020.710.29-0.270.560.620.210.650.02-0.04-0.39-0.870.69
-0.050.190.230.44-0.190.020.120.070.21-0.070.02-0.070.02-0.030.28-0.030.01-0.090.350.02-0.060.870.85-0.020.02
0.540.81-0.060.010.470.91-0.31-0.940.390.360.520.360.71-0.030.31-0.370.910.930.260.910.41-0.03-0.3-0.70.95
0.550.70.030.280.340.550.0-0.350.820.240.930.240.290.280.31-0.210.60.340.660.580.290.380.4-0.320.28
-0.45-0.27-0.18-0.22-0.36-0.290.380.56-0.25-0.41-0.27-0.41-0.27-0.03-0.37-0.21-0.35-0.55-0.3-0.29-0.430.110.010.23-0.25
0.670.88-0.020.130.540.91-0.3-0.860.670.430.770.430.560.010.910.6-0.350.850.470.920.480.05-0.09-0.560.85
0.750.73-0.060.00.710.81-0.59-1.00.450.640.530.640.62-0.090.930.34-0.550.850.250.810.68-0.16-0.28-0.640.79
0.360.490.760.890.00.420.02-0.290.620.140.650.140.210.350.260.66-0.30.470.250.440.170.170.42-0.180.28
0.50.97-0.010.110.361.0-0.12-0.830.60.240.710.240.650.020.910.58-0.290.920.810.440.290.09-0.16-0.740.91
0.950.27-0.06-0.010.950.27-0.95-0.640.521.00.371.00.02-0.060.410.29-0.430.480.680.170.29-0.20.05-0.020.2
-0.130.28-0.130.15-0.210.080.290.160.3-0.210.1-0.21-0.040.87-0.030.380.110.05-0.160.170.09-0.20.80.020.06
0.060.040.240.47-0.1-0.180.030.280.430.060.090.06-0.390.85-0.30.40.01-0.09-0.280.42-0.160.050.80.36-0.27
-0.18-0.720.060.06-0.13-0.78-0.10.67-0.060.03-0.450.03-0.87-0.02-0.7-0.320.23-0.56-0.64-0.18-0.74-0.020.020.36-0.66
0.340.82-0.010.070.260.91-0.1-0.810.370.150.460.150.690.020.950.28-0.250.850.790.280.910.20.06-0.27-0.66
Click cells to compare fundamentals

Marker Therapeutics Account Relationship Matchups

Marker Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets46.4M45.6M68.1M34.4M17.1M13.6M
Other Current Liab30.7K2.7M5.4M3.6M1.9M2.5M
Total Current Liabilities2.0M6.4M12.9M7.8M3.1M4.6M
Total Stockholder Equity44.1M27.3M44.0M19.6M14.1M7.1M
Property Plant And Equipment Net873.2K21.2M22.2M17.8M20.5M21.5M
Net Debt(43.4M)(9.1M)(30.5M)(4.2M)(15.1M)(14.4M)
Retained Earnings(327.5M)(356.2M)(398.1M)(428.0M)(436.3M)(414.5M)
Accounts Payable993K2.9M5.1M1.1M961K1.3M
Cash43.9M21.4M42.4M11.8M15.1M9.6M
Cash And Short Term Investments43.9M21.4M42.4M11.8M15.1M9.6M
Net Receivables56.2K1.0M237.02.4M1.0M1.1M
Common Stock Total Equity10.6K45.4K45.7K50.7K58.3K41.4K
Common Stock Shares Outstanding4.6M4.7M7.7M8.4M8.8M9.2M
Liabilities And Stockholders Equity46.4M45.6M68.1M34.4M17.1M13.6M
Non Current Liabilities Total1.6M280.2K11.9M11.2M7.0M0.0
Other Current Assets1.5M2.1M3.6M2.4M2.0M2.1M
Other Stockholder Equity371.6M383.5M442.0M447.6M450.3M472.8M
Total Liab2.3M18.3M24.1M14.8M3.1M6.0M
Property Plant And Equipment Gross873.2K21.2M24.9M17.8M20.5M21.5M
Total Current Assets45.5M24.4M46.0M16.6M17.1M10.3M
Short Term Debt204.1K777.6K1.2M577.2K663.8K714.4K
Common Stock45.7K50.7K83.1K8.4K8.9K8.4K
Non Currrent Assets Other(472.0)(21.2M)2.2M(17.8M)(16.0M)(15.2M)
Net Tangible Assets59.3M44.1M27.3M44.0M50.6M53.1M
Capital Surpluse161.1M365.4M371.6M383.5M441.1M230.6M
Net Invested Capital44.1M27.3M44.0M19.6M14.1M24.2M
Net Working Capital43.5M18.0M33.1M8.8M14.1M20.6M
Capital Stock45.7K50.7K83.1K8.4K8.9K8.4K

Pair Trading with Marker Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Marker Stock

  0.5MNOV MediciNovaPairCorr
  0.45MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.39FDMT 4D Molecular TherapeuticsPairCorr
  0.35NKTX Nkarta Inc Buyout TrendPairCorr
The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.
The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.